Moreover, unlike cTnI, MR-proANP was predictive for 180-day outcomes (mortality and MACEs, a composite of acute myocardial infarction, unstable angina pectoris, reinfarction, heart failure, and stroke) regardless of the type of MI. This evidence concerns the gene NPPA and intermediate coronary syndrome.